Get the Stockscreener App
2.52
7.69%
-0.21
Iovance Biotherapeutics Inc stock is traded at $2.52, with a volume of 14.99M.
It is down -7.69% in the last 24 hours and up +18.03% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.73
Open:
$2.78
24h Volume:
14.99M
Relative Volume:
1.07
Market Cap:
$1.00B
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-2.0488
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
-11.58%
1M Performance:
+18.03%
6M Performance:
+44.00%
1Y Performance:
-67.65%
1-Day Range:
$2.50
$2.82
1-Week Range:
$2.50
$2.885
52-Week Range:
$1.6385
$7.9747
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.52 | 1.08B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1%Here's What Happened - MarketBeat
Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review - Insider Monkey
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Will Iovance Biotherapeutics Inc. stock attract more institutional investorsCovered Call Writing & Budget Friendly Investment Plans - bollywoodhelpline.com
Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha
The next front against cancer: A Mugglehead roundup - Mugglehead Magazine
Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge? - Sahm
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025) - ts2.tech
Iovance Biotherapeutics: Is it Time to Invest? - StocksToTrade
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7%Still a Buy? - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
Will Iovance Biotherapeutics Inc. stock outperform Nasdaq indexTrade Analysis Summary & Community Verified Trade Signals - ulpravda.ru
Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC - MarketBeat
Aug Drivers: Why retail investors favor Iovance Biotherapeutics Inc. stockEntry Point & Fast Gain Stock Trading Tips - ulpravda.ru
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Why Iovance Biotherapeutics Inc. stock attracts high net worth investors - DonanımHaber
How Iovance Biotherapeutics Inc. (2LB) stock valuation compares with sectorGap Down & Weekly High Return Stock Opportunities - DonanımHaber
Iovance Biotherapeutics (IOVA): Assessing Valuation After FDA Progress, Melanoma Data and Upgraded Analyst Targets - Sahm
Insider Buy: Why retail investors favor Iovance Biotherapeutics Inc. stockJobs Report & Weekly Watchlist of Top Performers - Улправда
Market Trends: Is Iovance Biotherapeutics Inc. (2LB) stock cheap vs fundamentalsMarket Activity Report & Weekly High Return Forecasts - Улправда
There Is A Reason Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Price Is Undemanding - 富途牛牛
Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch - ts2.tech
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Barclays Maintains Iovance Biotherapeutics (IOVA) Overweight Recommendation - Nasdaq
Barclays Doubles Iovance Biotherapeutics’ Price Target in Bold Market Move - StocksToTrade
Iovance Biotherapeutics (IOVA) Sees Raised Price Target by Barcl - GuruFocus
Iovance Biotherapeutics Advances Innovative Melanoma Treatment with Updated Study - TipRanks
Barclays’ Bullish Outlook Sparks Iovance Stock Surge - timothysykes.com
Mirador Capital Partners LP Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7%Should You Buy? - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat
What analysts say about Iovance Biotherapeutics Inc 2LB stockLong-Term Investment Plans & Advanced Stock Screening Tools - earlytimes.in
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA)Contact Levi & Korsinsky Before July 14, 2025 - ACCESS Newswire
Iovance Biotherapeutics Stock: Analyzing Its Surprising Surge - StocksToTrade
Will Iovance Biotherapeutics’ Stock Surge? - timothysykes.com
Iovance Biotherapeutics: A Surge or A Signal to Watch? - timothysykes.com
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance
Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance
Voss Capital LP Acquires New Shares in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
With Iovance Biotherapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Finviz
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Stock Analysis & Fast Momentum Stock Entry Tips - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock benefits from AI revolutionJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser
What technical charts say about Iovance Biotherapeutics Inc. stock2025 Price Action Summary & Reliable Entry Point Trade Alerts - Newser
Will Iovance Biotherapeutics Inc. stock recover faster than peersWeekly Stock Summary & Verified Entry Point Signals - Newser
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
114,198 |
| BILINSKY IGOR | Chief Operating Officer |
Dec 02 '25 |
Option Exercise |
0.00 |
3,516 |
0 |
107,530 |
| BILINSKY IGOR | Chief Operating Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
108,478 |
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 02 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
468,948 |
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 01 '25 |
Option Exercise |
0.00 |
41,669 |
0 |
476,232 |
| Puri Raj K. | Chief Regulatory Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
218,326 |
| Vogt Frederick G | Interim CEO & General Counsel |
Sep 02 '25 |
Option Exercise |
0.00 |
52,086 |
0 |
456,690 |
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):